Fernanda S. Fidelis

Campinas, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

CGE26-144: Impact of OPRM1 Genetic Variants on Adverse Reactions and Opioid Switching in Lung Cancer Patients.

CGE26-144: Impact of OPRM1 Genetic Variants on Adverse Reactions and Opioid Switching in Lung Cancer Patients.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

CGE26-138: GSTP1 Variants and Ancestry as Predictors of Hematological Adverse Drug Reactions to Paclitaxel-Carboplatin Chemotherapy in Ovarian Cancer Patients.

CGE26-138: GSTP1 Variants and Ancestry as Predictors of Hematological Adverse Drug Reactions to Paclitaxel-Carboplatin Chemotherapy in Ovarian Cancer Patients.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CGE26-320: Influence of SLC Genes Variants and Patient Ancestry on Adverse Reactions Induced by Carboplatin and Paclitaxel in Patients With Lung Cancer.

CGE26-320: Influence of SLC Genes Variants and Patient Ancestry on Adverse Reactions Induced by Carboplatin and Paclitaxel in Patients With Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CGE26-137: Association Between Genetic Ancestry and TPMT/NUDT15 Phenotypes in Patients From Brazil's Unified Health System (SUS).

CGE26-137: Association Between Genetic Ancestry and TPMT/NUDT15 Phenotypes in Patients From Brazil's Unified Health System (SUS).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CGE26-138: GSTP1 Variants and Ancestry as Predictors of Hematological Adverse Drug Reactions to Paclitaxel-Carboplatin Chemotherapy in Ovarian Cancer Patients.

CGE26-138: GSTP1 Variants and Ancestry as Predictors of Hematological Adverse Drug Reactions to Paclitaxel-Carboplatin Chemotherapy in Ovarian Cancer Patients.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

CGE26-144: Impact of OPRM1 Genetic Variants on Adverse Reactions and Opioid Switching in Lung Cancer Patients.

CGE26-144: Impact of OPRM1 Genetic Variants on Adverse Reactions and Opioid Switching in Lung Cancer Patients.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

CGE26-320: Influence of SLC Genes Variants and Patient Ancestry on Adverse Reactions Induced by Carboplatin and Paclitaxel in Patients With Lung Cancer.

CGE26-320: Influence of SLC Genes Variants and Patient Ancestry on Adverse Reactions Induced by Carboplatin and Paclitaxel in Patients With Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

CGE26-137: Association Between Genetic Ancestry and TPMT/NUDT15 Phenotypes in Patients From Brazil's Unified Health System (SUS).

CGE26-137: Association Between Genetic Ancestry and TPMT/NUDT15 Phenotypes in Patients From Brazil's Unified Health System (SUS).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Pharmacogenetics of metamizole-induced agranulocytosis: a systematic review and drug regulation implications.

Pharmacogenetics of metamizole-induced agranulocytosis: a systematic review and drug regulation implications.

Journal: Frontiers in pharmacology

Published: May 06, 2025

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.

Journal: Scientific reports

Published: April 23, 2025

Association of ABC Efflux Transporter Genetic Variants and Adverse Drug Reactions and Survival in Patients with Non-Small Lung Cancer.

Association of ABC Efflux Transporter Genetic Variants and Adverse Drug Reactions and Survival in Patients with Non-Small Lung Cancer.

Journal: Genes

Published: March 12, 2025

Genetic Polymorphisms as Treatment Biomarkers for Gynecological Malignancies Treated With Carboplatin and Paclitaxel: A Systematic Review.

Genetic Polymorphisms as Treatment Biomarkers for Gynecological Malignancies Treated With Carboplatin and Paclitaxel: A Systematic Review.

Journal: Clinical therapeutics

Published: February 12, 2025

Showing 1-12 of 12

Last Updated: 09/26/2026